Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapaglifozin extended release - Lyndra

Drug Profile

Dapaglifozin extended release - Lyndra

Alternative Names: LYN‐045

Latest Information Update: 13 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lyndra
  • Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Obesity therapies; Pyrans; Small molecules; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 01 Nov 2020 Lyndra initiates a phase I trial in Type 2 diabetes mellitus (In volunteers) in Australia (PO) (ACTRN12620001187932)
  • 03 Dec 2019 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Australia (PO) (ACTRN12619001577101)
  • 15 Nov 2019 Lyndra plans a pharmacokinetic study in Type 2 diabetes mellitus (In volunteers) in Australia (PO) in November 2019 (ACTRN12619001577101)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top